Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.
Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment and Stigmatization
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Pointers With Portela: Minimalist Skin Care Routines
ReV Up Your Vitiligo Treatment Strategies
Experts Pen 12 Implementable Steps For Addressing Gender Inequity In Academic Dermatology
A Novel Approach to Distinguishing Scabies From Atopic Dermatitis